Soticlestat

Soticlestat (TAK-935; OV935) is a first-in-class, potent, selective, and orally active cholesterol 24-hydroxylase (CH24H) inhibitor. Soticlestat has the potential for epilepsy syndromes research[1][2].

Product Specifications

CAS Number

[1429505-03-2]

Product Name Alternative

TAK-935; OV935

UNSPSC

12352005

Hazard Statement

H302-H315-H319

Target

Cytochrome P450

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/soticlestat.html

Purity

99.83

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(N1CCC(CC2=CC=CC=C2)(O)CC1)C3=C(C4=CC=NC=C4)N=CC=C3

Molecular Formula

C23H23N3O2

Molecular Weight

373.45

Precautions

P264-P270-P280-P302+P352-P305+P351+P338-P330-P362+P364-P501

References & Citations

[1] Krista Eschbach, et al. Stiripentol for the treatment of seizures in Dravet syndrome. Expert Rev Clin Pharmacol. 2019 May;12 (5) :379-388.|[2]Toshiya Nishi, et al. Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice. Sci Rep. 2020 Oct 13;10 (1) :17081.